| Ytd | -15.70% | |
| 1y | 31.54% |
| Open | 3.70 | Prev Close | 3.69 | Low | 3.67 | High | 3.96 | Mkt Cap | 923.65M |
| Vol | 311.81K | Avg Vol | 673.72K | EPS | -2.16 | P/E | N/A | Forward P/E | -5.23 |
| Beta | 0.88 | Short Ratio | 2.14 | Inst. Own | 27.37% | Dividend | N/A | Div Yield | N/A |
| Ex Div Date | N/A | Earning | 03-30 | 50-d Avg | 4.61 | 200-d Avg | 5.19 | 1yr Est | 15.13 |
Inventiva (IVA) is technically in oversold territory now, so the heavy selling pressure might have e
Europe's largest independent growth debt fund manager has made an investment through its funds,
Claret Capital Partners is providing growth funding of €43m as part of Inventiva's €130m debt financ
Claret Capital Partners is providing growth funding of €43m as part of Inventiva's €130m debt financ
Daix (France), New York City (New York, United States), June 12, 2026 – Inventiva (Euronext Paris an
The heavy selling pressure might have exhausted for Inventiva (IVA) as it is technically in oversold
US stock futures lower, Nasdaq down 1%. Super Micro shares down 8.6% after announcing $7B offering t
Daix (France), New York City (New York, United States), June 9,2026 – Inventiva (Euronext Paris and
Secured a new debt financing with funds and accounts managed by BlackRock and Claret Capital Partner
Daix (France), New York City (New York, United States), June 2, 2026 – Inventiva (Euronext Paris an
Daix (France), New York City (New York, United States), June 2, 2026 – Inventiva (Euronext Paris and
Inventiva (NASDAQ:IVA) ("Inventiva" or the "Company"), a clinical-stage biopharmace
Daix (France), New York City (New York, United States), June 2, 2026 – Inventiva (Euronext Paris an
Daix (France), New York City (New York, United States), le 2 juin 2026 - Inventiva (Euronext Paris e
Daix (France), New York City (New York, United States), May 26, 2026 – Inventiva (Euronext Paris and
Daix (France), New York (United States), May 21, 2026 – Inventiva (Euronext Paris and NASDAQ: IVA) (
Inventiva is now essentially a lanifibranor bet. Their prospects hinge on the upcoming Phase 3 NATiV
Daix (France), New York City (New York, United States) , May 13, 2026 – Inventiva (Euronext Paris a
Daix (France), New York City (New York, Etats-Unis), le 13 mai 2026 - Inventiva (Euronext Paris et N
eGain AI Agent IVA replaces rigid dial trees with natural voice conversations, drawing on a governed
Recruitment of Chief Financial Officer, Chief Legal Officer, and Chief People Officer reflects Inven
U.S. stock futures rise on Tuesday with Dow futures up 400 points. Phreesia shares fall 26.5% in pre
Virgin Galactic reported Q4 revenue of $312,000, missing estimates, but beat EPS expectations. Its s
Inventiva (NASDAQ:IVA) reported quarterly losses of $(2.14) per share which missed the analyst conse
U.S. stock futures down, Zenas Biopharma shares fall 9.5% in pre-market trading due to pricing of pu
Newsmax Inc (NMAX) shares rose on better-than-expected Q4 results & FY26 sales guidance. Pre-mar
Wall Street analysts changed outlook on top names. Clear Street initiated coverage on RKLB with Buy
Truist Securities analyst Srikripa Devarakonda initiates coverage on Inventiva (NASDAQ:IVA) with
Barclays analyst Eliana Merle initiates coverage on Inventiva (NASDAQ:IVA) with a Overweight rati
Leerink Partners analyst Thomas Smith initiates coverage on Inventiva (NASDAQ:IVA) with a Outperf
Guggenheim analyst Seamus Fernandez maintains Inventiva (NASDAQ:IVA) with a Buy and lowers the pr
Following the exercise in full of the Underwriters' Option, the total number of ADSs issued in t
Inventiva (Euronext Paris and Nasdaq: IVA) ("Inventiva" or the "Company"), a clinica
Inventiva (Euronext Paris and Nasdaq: IVA) ("Inventiva" or the "Company"), a clinica
Wolfe Research analyst Steve Fleishman initiates coverage on Inventiva (NASDAQ:IVA) with a Outper